Episode 423: Understanding Infections and MS with Dr. Robert Fox
Release Date: 10/06/2025
RealTalk MS
One of the more confusing aspects of MS is that it can present differently from one person to the next. A research team at University College London may have uncovered a reason for that when they identified two new, and quite different, subtypes of MS. Joining me to walk us through this discovery and to explain how it may impact MS clinical care is the study's principal investigator, Dr. Arman Eshaghi. We're also sharing study results that may explain how the Epstein-Barr Virus triggers MS in some individuals. We'll tell you about the free online fitness and wellness...
info_outlineRealTalk MS
I don't have to remind anyone who listens to this podcast that the cost of MS disease-modifying therapies is obscenely high. And we're not just talking about relatively new medications. Older medications -- some decades old -- continue to increase in price without any rational explanation for why or how. On January 2nd, we lost a true warrior in the ongoing battle to lower the price of prescription drugs when David Mitchell, the founder of Patients for Affordable Drugs, passed away. I met David in 2018 at a National MS Society Public Policy Conference, and he was a guest...
info_outlineRealTalk MS
Scientists are expanding our understanding of MS at an unprecedented pace. This week, Dr. Leorah Freeman discusses why, as new discoveries and medications enter clinical practice, neurologists and MS specialists should ask themselves 3 important questions when considering a patient's treatment plan. Dr. Freeman is the Director of the Multiple Sclerosis and Neuroimmunology Center at Dell Medical School at the University of Texas at Austin, where she also leads the MS and Neuroimmunology fellowship program and the MS Imaging and Outcomes Research Laboratory. We'll also tell you about...
info_outlineRealTalk MS
We're closing out the year by revisiting the most listened-to episode of RealTalk MS in 2025. And it shouldn't come as a major surprise that this year's most listened-to episode was our review of the largest MS research conference in the world, ECTRIMS. This episode features the annual conversation that I have with Dr. Bruce Bebo, right outside of the conference center, just minutes after ECTRIMS adjourns. Dr. Bebo is the Executive Vice President of Research at the National MS Society, and each year, he very generously closes out 3 days of nonstop meetings,...
info_outlineRealTalk MS
The holiday season gives me the opportunity to indulge in what's become a RealTalk MS tradition. I reserve the last two episodes in December to revisit the most popular conversations that I've had over the past year. Women represent two-thirds of the MS population. Yet, surprisingly, there isn't nearly enough data related to women's health issues and MS. With an estimated 300,000 women living with MS in the United States who are currently in peri- or post-menopause, researchers have started to focus on how menopause and MS interact, and the best ways to treat symptoms...
info_outlineRealTalk MS
As the year draws to a close, we wanted to share some of the most compelling conversations we've had over the past 12 months. And rather than make my own picks, we went through the hundreds of emails we've received over the past year from the RealTalk MS listener community to see which topics really connected with you. In this week's episode, you'll hear from four of the top MS experts in the world discussing the subjects you've told me are most important to you. First, we'll explore aging and MS with Dr. John Corboy, the principal investigator of the largest study designed to answer...
info_outlineRealTalk MS
This special episode of RealTalk MS is sponsored by EMD Serono and is only intended for a U.S. audience. EMD Serono is the healthcare business of Merck, KGaA, Darmstadt, Germany, in the United States and Canada. Please note this episode is only intended for a U.S. audience. In this special episode of RealTalk MS, Professor Elisabeth Celius and Amanda Montague join me to explore new consensus recommendations for the future of MS care from MS in the 21st Century. We'll hear what experts and people in the MS community think are the priorities to focus on to improve care and help lessen the...
info_outlineRealTalk MS
Michael Jordan never won an NBA championship until he was paired with the right coach. Then, he won six. Could working with a coach change your MS journey? In this week's episode, health & wellness coach Amy Behimer explains what health coaching is all about and how working with a coach might impact someone living with MS. We're also sharing study results that show DMTs fail to manage MS-related pain. Then, we'll explain how a common misconception can lead to the wrong outcome for someone with MS. And we'll share study results showing that adhering to the Mediterranean or MIND diet...
info_outlineRealTalk MS
Welcome to a RealTalk MS special series on MS clinical trials. This special series is made possible through a generous grant from Sanofi. In this final episode of this series, you'll meet Jan Janisch-Hanzlik. Jan lives with MS and is a participant in one of the clinical trials evaluating the safety and efficacy of CAR-T cell therapy for MS. In CAR-T cell therapy, blood is taken from the patient or a healthy donor, much as you would donate blood. This blood is sent to a lab, where the white blood cells, or T-cells, are separated out and reprogrammed to carry a receptor designed to...
info_outlineRealTalk MS
At the age of 14, Michaela Janssen Pohl became a caregiver for her mother, who lives with MS. I think most of us can agree that just being a teenager carries with it more than enough challenges. Those adolescent years are the years when just about everything in life starts changing. Imagine adding the responsibilities of being a caregiver to all the other things going on in a 14-year-old girl's life. Michaela joins me this week to explain how she found ways to survive and thrive in what can only be described as a challenging situation for any teenager. We'll also explain why you might want to...
info_outlineFrom the earliest days of the COVID-19 pandemic, people living with MS have been justifiably concerned about how a COVID-19 infection might impact their MS. As the new "Stratus" strain of COVID-19 is currently surging in the United States, research is providing answers we didn't have five years ago.

Dr. Robert Fox, the Managing Director of the NARCOMS Patient Registry, joins me to discuss how COVID-19 infections and other infections impact people with MS.
As ECTRIMS, the world's largest MS research conference, approached, many attendees anticipated the FDA's decision on whether to approve Tolebrutinib, the first in a new category of disease-modifying therapies. Instead, the FDA has requested additional time for its review. We'll fill you in on the FDA's new target action date, and explain why there's strong interest in this particular disease-modifying therapy.
We know there's a specific gene that increases the risk of someone developing MS. But have you ever wondered where that gene came from, or why it exists at all? At ECTRIMS, Professor Lars Fugger took us on a journey 5,000 years into the past to explain its origin. When I spoke with him, Professor Fugger also explained how events from ancient history are still affecting the risk of developing MS today. You won't want to miss this compelling conversation!
At ECTRIMS, I also caught up with Jason Tardio, the President, and Dr. Andreas Muehler, the Chief Medical Officer, from Immunic Therapeutics. We talked about how their investigative drug, vidofludimus calcium, could potentially benefit people with MS by combating inflammation, protecting the nervous system, and offering antiviral benefits.
We have a lot to talk about! Are you ready for RealTalk MS??!
This Week: Infections and MS, and more from ECTRIMS 2025! :22
FDA extends its review of Tolebrutinib 1:42
From ECTRIMS: Professor Lars Fugger discusses the origin of the gene that increases an individual's risk of developing MS 4:11
From ECTRIMS: Jason Tardio, President, and Dr. Andreas Muehler, Chief Medical Officer, at Immunic Therapeutics, discuss how vidofludimus calcium could potentially benefit people with MS 11:22
Dr. Robert Fox discusses what the research reveals about how COVID-19 infections and other infections impact people living with MS 16:34
Share this episode 32:00
Next week's episode 32:19
SHARE THIS EPISODE OF REALTALK MS
Just copy this link & paste it into your text or email: https://realtalkms.com/423
ADD YOUR VOICE TO THE CONVERSATION
I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!
Email: jon@realtalkms.com
Phone: (310) 526-2283
And don't forget to join us in the RealTalk MS Facebook group!
LINKS
If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com
PARTICIPATE: Take the Shaping Tomorrow Together Survey
https://s.alchemer.com/s3/Perspectives-on-MS
REGISTER: Attend the virtual Shaping Tomorrow Together meeting with the FDA
https://nmss.quorum.us/event/25463
SIGN UP: Become an MS Activist
https://nationalmssociety.org/advocacy
JOIN: The RealTalk MS Facebook Group
https://facebook.com/groups/realtalkms
DOWNLOAD: The RealTalk MS App for iOS Devices
https://itunes.apple.com/us/app/realtalk-ms/id1436917200
DOWNLOAD: The RealTalk MS App for Android Devices
https://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk
REVIEW: Give RealTalk MS a rating and review
http://www.realtalkms.com/review
Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.
RealTalk MS Episode 423
Guests: Professor Lars Fugger, Jason Tardio, Dr. Andreas Meuhler, and Dr. Robert Fox